Madrigal Pharmaceuticals (MDGL) Assets (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Assets for 17 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Assets rose 22.58% year-over-year to $1.2 billion; the TTM figure through Jun 2026 stood at $1.2 billion (up 22.58% YoY), while the FY2025 annual figure was $1.3 billion, up 20.85% from the prior year.
• Assets improved to $1.2 billion in Q2 2026 per MDGL's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Assets topped out at $1.4 billion in Q3 2025 and bottomed at $158.6 million in Q3 2022.
• Historically, Assets has averaged $771.0 million across 5 years, with a median of $1.0 billion in 2025.
• Annual changes were most pronounced in 2022 — Assets tumbled 47.93% — and 2024, when it jumped 351.02%.
• Madrigal Pharmaceuticals' Assets stood at $362.6 million in 2022, then soared by 76.67% to $640.5 million in 2023, then soared by 62.71% to $1.0 billion in 2024, then gained by 20.85% to $1.3 billion in 2025, then declined by 1.19% to $1.2 billion in 2026.
• Business Quant data shows MDGL's Assets at $1.2 billion in Q2 2026, $1.2 billion in Q1 2026, and $1.3 billion in Q4 2025.